Insmed Incorporated, a global biopharmaceutical company dedicated to improving the lives of those with serious and rare diseases, is thrilled to announce the granting of inducement awards to 24 new employees.
To ensure compliance with NASDAQ Listing Rule 5635(c)(4), Insmed’s Compensation Committee approved the awards as a way to welcome the new employees and show appreciation for their commitment to joining the Company.
On April 3, 2023, Insmed welcomed its new employees with a special gift – options to purchase 182,880 shares of the company’s common stock at an exercise price of $17.37 per share, reflecting the closing trading price on the Nasdaq Global Select Market on the date of grant.
Options granted by Insmed have a 10-year term and a four-year vesting schedule, meaning that 25% of the shares subject to the option vest after the first anniversary of the grant date, and then 12.5% of the shares vest every six months until the fourth anniversary, provided the relevant employee remains in service with Insmed.
Insmed Incorporated is on a mission to revolutionize the lives of patients suffering from serious and rare diseases. As the first to introduce a first-in-disease therapy to treat a chronic, debilitating lung disease, their product has been approved in the United States, Europe, and Japan.
But that’s not all – Insmed is furthering their ambition by exploring a cutting-edge pipeline of investigational therapies to tackle areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Headquartered in Bridgewater, New Jersey with a global presence, Insmed is poised to be a leader in the healthcare industry.